Tag:
therapeutic goods administration
Latest Headlines
Latest Headlines
Abbott pulls Meridia in multiple markets
At the request of the FDA, Abbott Laboratories is voluntarily withdrawing Meridia (sibutramine) from the U.S. market following concerns that the drug may increase risk of serious cardiovascular
